Literature DB >> 15070688

Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase.

Hiroshi Fujiwara1, Frank El Ouriaghli, Matthias Grube, David A Price, Katayoun Rezvani, Emma Gostick, Giuseppe Sconocchia, Jos Melenhorst, Nancy Hensel, Daniel C Douek, A John Barrett.   

Abstract

Human neutrophil elastase (HNE) and proteinase 3 (PRO3) are myeloid tissue-restricted serine proteases, aberrantly expressed by myeloid leukemia cells. PRO3 and HNE share the PR1 peptide sequence that induces HLA-A*0201-restricted cytotoxic T cells (CTLs) with antileukemia reactivity. We studied the entire HNE protein for its ability to induce CTLs. In an 18-hour culture, HNE-loaded monocytes stimulated significant intracellular interferon gamma (IFN-gamma) production by CD4+ and CD8+ T cells in 12 of 20 and 8 of 20 healthy individuals, respectively. Lymphocytes from 2 HNE responders were pulsed weekly for 4 weeks to generate HNE-specific CTLs. One of 2 HLA-A*0201-negative individuals inhibited the colony formation of HLA-identical chronic myelogenous leukemia progenitor cells (73% inhibition at 50:1 effector-target [E/T] ratio), indicating that peptides other than PR1 can induce leukemia-reactive CTLs. Repetitive stimulations with HNE in 2 of 5 HLA-A*0201+ individuals increased PR1 tetramer-positive CD8+ T-cell frequencies from 0.1% to 0.29% and 0.02% to 0.55%, respectively. These CTLs recognized PR1 peptide or killed HNE-loaded targets. These results indicate that exogenously processed HNE is a source of PR1 peptide as well as other peptide sequences capable of inducing leukemia-specific CD8+ and CD4+ T cells. HNE could, therefore, be used in an HLA-unrestricted manner to induce leukemia-reactive CTLs for adoptive immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15070688     DOI: 10.1182/blood-2003-07-2424

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

Review 1.  Strategies for the identification of T cell-recognized tumor antigens in hematological malignancies for improved graft-versus-tumor responses after allogeneic blood and marrow transplantation.

Authors:  Jenny Zilberberg; Rena Feinman; Robert Korngold
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-20       Impact factor: 5.742

Review 2.  Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie Bleakley; Cameron J Turtle; Stanley R Riddell
Journal:  Expert Rev Hematol       Date:  2012-08       Impact factor: 2.929

Review 3.  Immunology and immunotherapy of chronic myeloid leukemia.

Authors:  Mette Ilander; Can Hekim; Satu Mustjoki
Journal:  Curr Hematol Malig Rep       Date:  2014-03       Impact factor: 3.952

4.  Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.

Authors:  Simon F Lacey; Corinna La Rosa; Teodora Kaltcheva; Tumul Srivastava; Aprille Seidel; Wendi Zhou; Ravindra Rawal; Katharine Hagen; Aparna Krishnan; Jeff Longmate; Helen A Andersson; Lisa St John; Ravi Bhatia; Vinod Pullarkat; Stephen J Forman; Laurence J N Cooper; Jeffrey Molldrem; Don J Diamond
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

Review 5.  Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.

Authors:  A J Barrett; K Rezvani
Journal:  Clin Exp Immunol       Date:  2007-05       Impact factor: 4.330

6.  The role of antigen cross-presentation from leukemia blasts on immunity to the leukemia-associated antigen PR1.

Authors:  Gheath Alatrash; Yoko Ono; Anna Sergeeva; Pariya Sukhumalchandra; Mao Zhang; Lisa S St John; Tian-Hui Yang; Kathryn Ruisaard; Paul M Armistead; Elizabeth A Mittendorf; Hong He; Na Qiao; Tania Rodriguez-Cruz; Shoudan Liang; Karen Clise-Dwyer; Eric D Wieder; Gregory Lizee; Sijie Lu; Jeffrey J Molldrem
Journal:  J Immunother       Date:  2012-05       Impact factor: 4.456

7.  Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant.

Authors:  G Weber; U Gerdemann; I Caruana; B Savoldo; N F Hensel; K R Rabin; E J Shpall; J J Melenhorst; A M Leen; A J Barrett; C M Bollard
Journal:  Leukemia       Date:  2013-03-01       Impact factor: 11.528

Review 8.  Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease.

Authors:  Chikashi Yoshida; Junia V Melo
Journal:  Int J Hematol       Date:  2004-06       Impact factor: 2.490

9.  Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy.

Authors:  A S M Yong; K Keyvanfar; R Eniafe; B N Savani; K Rezvani; E M Sloand; J M Goldman; A J Barrett
Journal:  Leukemia       Date:  2008-06-12       Impact factor: 11.528

10.  High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects.

Authors:  Agnes S M Yong; Katayoun Rezvani; Bipin N Savani; Rhoda Eniafe; Stephan Mielke; John M Goldman; A John Barrett
Journal:  Blood       Date:  2007-04-05       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.